

# Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

## CD209b (SIGN-R1) Antibody, APC-Vio® 770, REAfinity™

RRID:AB\_2656268

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-106-406, RRID:AB\_2656268

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2656268](http://antibodyregistry.org/AB_2656268)

**Proper Citation:** Miltenyi Biotec Cat# 130-106-406, RRID:AB\_2656268

**Target Antigen:** CD209b (SIGN-R1)

**Host Organism:** human

**Clonality:** recombinant

**Comments:** Discontinued: 11-2020; Applications: MACS Flow Cytometry  
Antigen Distribution: macrophages, spleen, lymphocytes, other

**Antibody Name:** CD209b (SIGN-R1) Antibody, APC-Vio® 770, REAfinity™

**Description:** This recombinant targets CD209b (SIGN-R1)

**Target Organism:** mouse

**Clone ID:** [REA125]

**Antibody ID:** AB\_2656268

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-106-406

**Record Creation Time:** 20231110T034427+0000

**Record Last Update:** 20260901T020113+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD209b (SIGN-R1) Antibody, APC-Vio® 770, REAfinity™.

**Warning:** Discontinued: 2021

Discontinued: 11-2020; Applications: MACS Flow Cytometry

Antigen Distribution: macrophages, spleen, lymphocytes, other

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Mauvais FX, et al. (2025) Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors. Immunity, 58(4), 843.